Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setipiprant in Androgenetic Alopecia
NCT02781311Phase 2Completed
- Sponsor
- Allergan
- Start
- Jul 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setipiprant in androgenetic alopecia (AGA) (3 arms), sponsored by Allergan. Primary endpoints: Target Area Hair Count at 24 weeks and Subject Self-Assessment at 24 weeks. Started Jul 2016; status: completed.
02
Drugs
setipiprant
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT02781311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781311.